FrancophonIA/ELRC3.0 huggingface dataset:
English: Edible Green Ink contains: Black Iron Oxide-Synthetic (E172) Yellow Iron Oxide- Synthetic (E172) Propylene glycol
Estonian: Farmatseutiline roheline toiduvärvsisaldab: sünteetilist musta raudoksiidi (E172) sünteetilist kollast raudoksiidi (E172) propüleenglükooli šellakit.
English: • depression, anxiety and urinary incontinence.
Estonian: • depressiooni episoodid, ärevus ja stress - kusepidamatus
English: Furthermore, increases in INR values have been reported when duloxetine was co-administered to patients treated with warfarin.
Estonian: Peale selle on duloksetiini koosmanustamisel varfariiniga teatatud INR tõusudest.
English: There have been reports of bleeding abnormalities, such as ecchymoses, purpura and gastrointestinal haemorrhage with selective serotonin reuptake inhibitors (SSRIs) and serotonin/noradrenaline reuptake inhibitors (SNRIs).
Estonian: Selektiivsete serotoniini tagasihaarde inhibiitorite (SSTI) ja serotoniini/noradrenaliini tagasihaarde inhibiitorite (SNTI) puhul on täheldatud veritsusehäireid nagu ekhümoosid, purpur ja gastrointestinaalne veritsus.
English: Caution is advisable if DULOXETINE BOEHRINGER INGELHEIM is used concomitantly with serotonergic antidepressants like SSRIs, tricyclics like clomipramine or amitriptyline, St John's wort (Hypericum perforatum), venlafaxine or triptans, tramadol, pethidine and tryptophan.
Estonian: DULOXETINE BOEHRINGER INGELHEIM`i manustamisel koos serotoniinergiliste antidepressantide, nt SSTItega, tritsükliliste antidepressantide, nt klomipramiini või amitriptüliiniga, naistepuna ürdiga (Hypericum perforatum), venlafaksiini või triptaanidega, tramadooli, petidiini ja trüptofaaniga soovitatakse olla eriti tähelepanelik.
English: Edible White Ink contains: Titanium Dioxide (E171) Propylene glycol Shellac
Estonian: Farmatseutiline valge toiduvärv sisaldab: Titaandioksiid (E171) propüleenglükooli šellakit povidoon
English: MARKETING AUTHORISATION NUMBER(S) EU/1/08/471/003
Estonian: MÜÜGILOA NUMBER(NUMBRID) EU/1/08/471/003
English: DULOXETINE BOEHRINGER INGELHEIM 30 mg is available in packs of 7, 28 and 98 capsules.
Estonian: DULOXETINE BOEHRINGER INGELHEIM 30 mg on saadaval 7, 28 ja 98 kapsli kaupa pakendites.
English: Night sweats Urticaria Dermatitis contact Cold sweat Photosensitivity reactions Increased tendency to bruise
Estonian: Öine higistamine Urtikaaria Dermatiit Külm higi Valgustundlikkus
English: • become pregnant, or you are trying to become pregnant, while you are taking DULOXETINE BOEHRINGER INGELHEIM.
Estonian: • olete DULOXETINE BOEHRINGER INGELHEIM`i ravi ajal rasestunud või soovite rasestuda,
English: 5 How to store DULOXETINE BOEHRINGER INGELHEIM Further information
Estonian: DULOXETINE BOEHRINGER INGELHEIM`i säilitamine Lisainfo
English: • muscle pain, muscle tightness, muscle spasm
Estonian: • lihasvalu, lihaste, jäikus, spasmid
English: Hyponatremia
Estonian: Hüponatreemia
English: MARKETING AUTHORISATION NUMBER(S) EU/1/08/471/011-012
Estonian: MÜÜGILOA NUMBER(NUMBRID) EU/1/08/471/0111/08/471/001-012
English: Sodium Lauryl Sulfate Titanium Dioxide (E171) Indigo Carmine (E132) Yellow Iron Oxide (E172) Edible White Ink
Estonian: Naatriumlaurüülsulfaat titaandioksiid (E171) indigokarmiin (E132) kollane raudoksiid (E172) farmatseutiline valge toiduvärv
English: Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine.
Estonian: Enne igasuguse ravimi võtmist pidage nõu arsti või apteekriga.
English: Urinary Retention Dysuria Urinary hesitation Nocturia Polyuria Urine flow decreased
Estonian: Kusepeetus Düsuuria Pakitsustunne urineerimisel Nüktuuria Polüuuria Uriinijoa nõrkus
English: Taking DULOXETINE BOEHRINGER INGELHEIM with food and drink DULOXETINE BOEHRINGER INGELHEIM may be taken with or without food.
Estonian: DULOXETINE BOEHRINGER INGELHEIM'i võib võtta koos toiduga või ilma.
English: Do not pass it on to others.
Estonian: - Ravim on välja kirjutatud isiklikult teile ja seda ei tohi anda kellelegi teisele.
English: • having abnormal urine odour
Estonian: • uriini ebatavaline lõhn
English: MAOI.
Estonian: MUU
English: Although DULOXETINE BOEHRINGER INGELHEIM is not indicated for the treatment of depression, its active ingredient (duloxetine) also exists as an antidepressant medication.
Estonian: Depressioon, suitsidaalsed mõtted ja suitsidaalne käitumine Kuigi DULOXETINE BOEHRINGER INGELHEIM ei ole näidustatud depressiooni raviks, kasutatakse sama toimeainet (duloksetiini) ka antidepressiivse ravimina.
English: Very common side effects (these can affect more than 10 in 100 patients treated)
Estonian: Sagedased kõrvaltoimed (võivad esineda 1-10 patsiendil 100-st)
English: • blurred eyesight
Estonian: • hägune silmanägemine
English: Do not take more than the daily amount of DULOXETINE BOEHRINGER INGELHEIM that has been prescribed for you in one day.
Estonian: Ärge võtke DULOXETINE BOEHRINGER INGELHEIM'i korraga rohkem, kui on ettekirjutatud.
English: It may harm them, even if their symptoms are the same as yours - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
Estonian: - Kui ükskõik milline kõrvaltoimetest muutub tõsiseks või kui te märkate mõnda kõrvaltoimet,
English: You should use DULOXETINE BOEHRINGER INGELHEIM only after discussing the potential benefits and any potential risks to your unborn child with your doctor.
Estonian: Enne DULOXETINE BOEHRINGER INGELHEIM`i kasutamist rääkige oma arstiga võimalikust kasust ja riskidest lootele.
English: Sodium Lauryl Sulfate Titanium Dioxide (E171) Indigo Carmine (E132) Edible Green Ink
Estonian: Naatriumlaurüülsulfaat titaandioksiid (E171) indigokarmiin (E132) farmatseutiline roheline toiduvärv
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTONS FOR 30 MG HARD GASTRO-RESISTANT CAPSULES
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED VÄLISPAKEND 30 MG GASTRORESISTENTSED KÕVAKAPSLID
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 30 mg of duloxetine (as hydrochloride)
Estonian: TOIMEAINE(TE) SISALDUS Iga kapsel sisaldab 30 mg duloksetiini (vesinikkloriidina)
English: • weight gain
Estonian: • suurenenud surve silmas
English: Hypothyroidism
Estonian: Hüpromelloos
English: Renal insufficiency
Estonian: Maksapuudulikkus:
English: Hypertension Hypertensive crisis
Estonian: Veetustumine Hüponatreemia
English: Always take DULOXETINE BOEHRINGER INGELHEIM exactly as your doctor has told you.
Estonian: KUIDAS VÕTTA DULOXETINE BOEHRINGER INGELHEIM'i Võtke DULOXETINE BOEHRINGER INGELHEIM'i alati vastavalt arstilt saadud juhistele.
English: Gastrointestinal Disorders Nausea (24.3%) Dry mouth
Estonian: Unisus(10,7%) Uimasus
English: Blurred vision Mydriasis Visual disturbance
Estonian: Müdriaas Nägemishäired
English: The following are reasons why DULOXETINE BOEHRINGER INGELHEIM may not be suitable for you.
Estonian: Eriline ettevaatus on vajalik ravimiga DULOXETINE BOEHRINGER INGELHEIM: Järgnevalt on toodud põhjused, miks DULOXETINE BOEHRINGER INGELHEIM teile ei sobi.
English: DULOXETINE BOEHRINGER INGELHEIM may make you feel sleepy of dizzy.
Estonian: DULOXETINE BOEHRINGER INGELHEIM võib tekitada unisust või uimasust.
English: Anxiety
Estonian: Tähelepanuhäire
English: If you forget to take DULOXETINE BOEHRINGER INGELHEIM If you miss a dose, take it as soon as you remember.
Estonian: Kui te unustate annuse võtmata, võtke see niipea, kui meenub.
English: DULOXETINE BOEHRINGER INGELHEIM may be associated with sedation and dizziness.
Estonian: DULOXETINE BOEHRINGER INGELHEIM`i kasutamisega võib kaasneda sedatsioon ja uimasus.
English: DO NOT take DULOXETINE BOEHRINGER INGELHEIM if you:
Estonian: Kui te unustate DULOXETINE BOEHRINGER INGELHEIM'i võtta:
English: Care should be taken if you drink alcohol while you are being treated with DULOXETINE BOEHRINGER INGELHEIM.
Estonian: Teil tuleb DULOXETINE BOEHRINGER INGELHEIM ravi ajal olla ettevaatlik alkoholi tarbimisega.
English: The PSUR cycle of Duloxetine Boehringer Ingelheim will correspond to the one attributed to the cross-referred product, Ariclaim, until otherwise specified.
Estonian: Kui ei ole teisiti kokku lepitud, vastab Duloxetine Boehringer Ingelheim`i POA tsükkel samaaegselt turustatavale tootele Ariclaim`ile.
English: Haemorrhage
Estonian: Lihasjäikus
English: Undesirable effects may be more common during concomitant use of DULOXETINE BOEHRINGER INGELHEIM and herbal preparations containing St John's wort (Hypericum perforatum).
Estonian: DULOXETINE BOEHRINGER INGELHEIM `i ja naistepuna (Hypericum perforatum) sisaldavate taimsete preparaatide samaaegsel kasutamisel võib kõrvaltoimeid esineda sagedamini.
English: HOW TO STORE DULOXETINE BOEHRINGER INGELHEIM Keep out of the reach and sight of children
Estonian: DULOXETINE BOEHRINGER INGELHEIM`i SÄILITAMINE Hoida laste eest varjatud ja kättesaamatus kohas!
English: What DULOXETINE BOEHRINGER INGELHEIM looks like and contents of the pack DULOXETINE BOEHRINGER INGELHEIM is a hard gastro-resistant capsule Each capsule of DULOXETINE BOEHRINGER INGELHEIM contains pellets of duloxetine hydrochloride with a covering to protect them from stomach acid.
Estonian: Kuidas DULOXETINE BOEHRINGER INGELHEIM välja näeb ja pakendi sisu DULOXETINE BOEHRINGER INGELHEIM on gastroresistentne kõvakapsel.
English: please tell your doctor or pharmacist
Estonian: mida selles infolehes ei ole nimetatud, palun rääkige sellest oma arstile või apteekrile.
English: Use in children and adolescents under 18 years of age No clinical trials have been conducted with duloxetine in paediatric populations.
Estonian: Pediaatrilisel populatsioonil ei ole duloksetiiniga kliinilisi uuringuid läbi viidud.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 60 mg of duloxetine (as hydrochloride)
Estonian: TOIMEAINE(TE) SISALDUS Iga kapsel sisaldab 60 mg duloksetiini vesinikkloriidina
English: Tremor Paraesthesia
Estonian: Ejakulatsiooni häired
English: Hard gastro-resistant capsule.
Estonian: Gastroresistentsed kõvakapslid.
English: PACKAGE LEAFLET: INFORMATION FOR THE USER DULOXETINE BOEHRINGER INGELHEIM 30 mg hard gastro-resistant capsules DULOXETINE BOEHRINGER INGELHEIM 60 mg hard gastro-resistant capsules Duloxetine (as hydrochloride)
Estonian: DULOXETINE BOEHRINGER INGELHEIM 30 mg gastroresistentsed kõvakapslid DULOXETINE BOEHRINGER INGELHEIM 60 mg gastroresistentsed kõvakapslid
English: NAME OF THE MEDICINAL PRODUCT DULOXETINE BOEHRINGER INGELHEIM 30 mg hard gastro-resistant capsules
Estonian: RAVIMPREPARAADI NIMETUS DULOXETINE BOEHRINGER INGELHEIM 30 mg gastroresistentsed kõvakapslid
English: NAME OF THE MEDICINAL PRODUCT DULOXETINE BOEHRINGER INGELHEIM 60 mg hard gastro-resistant capsules
Estonian: RAVIMPREPARAADI NIMETUS DULOXETINE BOEHRINGER INGELHEIM 60 mg gastroresistentsed kõvakapslid
English: Hyponatremia has been reported rarely, predominantly in the elderly, when administering DULOXETINE BOEHRINGER INGELHEIM.
Estonian: DULOXETINE BOEHRINGER INGELHEIM`i kasutamisel on harva täheldatud hüponatreemiat, peamiselt eakatel.
English: • CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON
Estonian: • MÜÜGILOA HOIDJALE ESITATUD HANKE- JA KASUTUSTINGIMUSED JAPIIRANGUD
English: BEFORE YOU TAKE DULOXETINE BOEHRINGER INGELHEIM
Estonian: MIDA ON VAJA TEADA ENNE DULOXETINE BOEHRINGER INGELHEIM VÕTMIST
English: Duloxetine is very weakly excreted into human milk based on a study of 6 lactating patients, who did not breast feed their children .
Estonian: Uuringu põhjal, kus osales 6 lakteerivat patsienti, kes oma lapsi ei imetanud, leiti, et duloksetiin eritub väga väheses koguses rinnapiima.
English: • passing bright red blood in your stools, vomiting blood, or black tarry stools (faeces)
Estonian: • helepunase vere roojamine, vere oksendamine või süsimusta väljaheite roojamine
English: PSURs
Estonian: Lööve
English: You must wait at least 14 days after you have stopped taking an MAOI before you can take DULOXETINE BOEHRINGER INGELHEIM.
Estonian: Pärast MAOI ärajätmist ja enne DULOXETINE BOEHRINGER INGELHEIM kasutamist peate te ootama vähemalt 14 päeva.
English: Hypromellose Acetate Succinate Sucrose
Estonian: Hüpromelloosi atsetaatsuktsinaat Sahharoos
English: The 30 mg capsules has an opaque white body, imprinted with ‘30 mg' and an opaque blue cap, imprinted with ‘9543'.
Estonian: DULOXETINE BOEHRINGER INGELHEIM on saadaval 2 tugevusena: 30 mg ja 60 mg. 30 mg kapslitel on läbipaistmatu valge põhiosa, märgistusega `30 mg` ja läbipaistmatu sinine kate, märgistusega `9543`.
English: Blood pressure increase Peripheral coldness Orthostatic hypotension2 Syncope2
Estonian: Vaskulaased haired Õhetamine Vererõhu tõus Perifeerne külmatunne
English: Monoamine Oxidase Inhibitors (MAOIs): You should not take DULOXETINE BOEHRINGER INGELHEIM if you are taking, or have recently taken within the last 14 days, another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Estonian: Ärge võtke DULOXETINE BOEHRINGER INGELHEIM'i: - kui te olete allergiline (ülitundlik) duloksetiini või mõne DULOXETINE BOEHRINGER INGELHEIM koostisosa suhtes - kui teil esineb maksahaigus - kui te kasutate või olete eelnevalt vähem kui 14 päeva tagasi kasutanud teist ravimit, mida nimetatakse monoamiini oksüdaasi inhibiitoriks - MAOI (vt ka alljärgnevat lõiku`Kasutamine koos teiste ravimitega`) - kui kasutate fluvoksamiini, mida tavaliselt kasutatakse depressiooni raviks, tsiprofloksatsiini või enoksatsiini, mida kasutatakse mõnede põletike raviks.
English: Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.
Estonian: 25-aastastel psühhiaatrilise seisundiga täiskasvanutel esineb suurenenud suitsidaalse käitumise oht.
English: Important information about some of the ingredients of DULOXETINE BOEHRINGER INGELHEIM
Estonian: Oluline informatsioon DULOXETINE BOEHRINGER INGELHEIM abiainete kohta: DULOXETINE BOEHRINGER INGELHEIM sisaldab sahharoosi.
English: NAME OF THE MEDICINAL PRODUCT DULOXETINE BOEHRINGER INGELHEIM 60 mg hard gastro-resistant capsules Duloxetine
Estonian: DULOXETINE BOEHRINGER INGELHEIM 60 mg gastroresistentsed kõvakapslid Duloksetiin
English: NAME OF THE MEDICINAL PRODUCT DULOXETINE BOEHRINGER INGELHEIM 30 mg hard gastro-resistant capsules Duloxetine
Estonian: DULOXETINE BOEHRINGER INGELHEIM 30 mg gastroresistentsed kõvakapslid Duloksetiin
English: Muscle
Estonian: Lihasspasm
English: • burping, indigestion, gastroenteritis
Estonian: • röhitsemine, seedimatus, maopõletik
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 30 mg of duloxetine (as hydrochloride) Excipients: sucrose 8.6 mg.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Iga kapsel sisaldab 30 mg duloksetiini (vesinikkloriidina).
English: • dehydration
Estonian: • sagenenud haigutamine
English: It was to be available as tablets (125 mg and 250 mg).
Estonian: Ravimit kavatseti turustada tablettidena (125 mg ja 250 mg).
English: The main measure of effectiveness is the number of patients who respond to treatment.
Estonian: Efektiivsuse põhinäitaja oli ravivastusega patsientide arv.
English: What is Xegafri?
Estonian: Mis on Xegafri?
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom27 May 2016
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom27.
English: EGFR controls growth and division of cells.
Estonian: EGFR reguleerib rakkude kasvu ja jagunemist.
English: The company will continue to provide Xegafri to patients whose doctor recommend they should continue to take this medicine.
Estonian: Ettevõte jätkab Xegafri tarnimist patsientidele, kelle arst on soovitanud jätkata selle ravimi võtmist.
English: The data provided were too limited to enable evaluation of the effectiveness of Xegafri at this time.
Estonian: Esitatud andmed olid ebapiisavad, et sel ajal saanuks hinnata Xegafri efektiivsust.
English: In these studies, Xegafri is not compared with any other treatment.
Estonian: Neis uuringutes ei võrreldud Xegafrit muude ravimitega.
English: In its letter notifying the Agency of the withdrawal of application, the company stated that it was withdrawing its application because of a revised business strategy for the product.
Estonian: Kirjas, milles ettevõte teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, märgib ettevõte, et võtab taotluse tagasi tootega seotud äristrateegia muutumise tõttu.
English: In lung cancer cells, EGFR is often overactive, causing uncontrolled division of cancer cells.
Estonian: Kopsuvähi rakkudes on EGFR sageli liiga aktiivne, põhjustades vähirakkude kontrollimatut jagunemist.
English: Withdrawal of the marketing authorisation application for Xegafri (rociletinib) EMA/352428/2016
Estonian: Müügiloa taotluse tagasivõtmise teave: Xegafri (rosiletiniib) EMA/352428/2016
English: In addition, QT prolongation (a change in the heart's electrical activity) and cases of serious heart problems presented a safety concern.
Estonian: Lisaks oli ohutusprobleemiks QT-intervalli pikenemine (südame elektrilise talitluse teatud muutus) ja raskete südameprobleemide esinemine.
English: The company informed the CHMP that they will stop enrolling patients in the ongoing clinical trials.
Estonian: Ettevõte teatas inimravimite komiteele, et patsientide värbamine toimuvatesse kliinilistesse uuringutesse peatatakse.
English: Xegafri is a medicine that contains the active substance rociletinib.
Estonian: Xegafri on ravim, mis sisaldab toimeainena rosiletiniibi.
English: Withdrawal of the marketing authorisation application for Xegafri (rociletinib)
Estonian: Müügiloa taotluse tagasivõtmise teave: Xegafri (rosiletiniib)
English: On 3 May 2016, Clovis Oncology UK Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Xegafri, for the treatment of non-small cell lung cancer.
Estonian: Clovis Oncology UK Ltd teatas 3. mail 2016 ametlikult inimravimite komiteele oma soovist võtta tagasi Xegafri müügiloa taotlus.
English: By blocking the tyrosine kinase in EGFR, rociletinib is expected to help reduce the growth and spread of the cancer.
Estonian: EGFRi türosiinkinaasi blokeerides aitab rosiletiniib aeglustada vähi kasvu ja levikut.
English: In addition, patients currently receiving Xegafri through a compassionate use programme can continue to receive this medicine.
Estonian: Samuti tohivad praegu Xegafrit eriloaga kasutamise programmiga kasutavad patsiendid ravimi võtmist jätkata.
English: Xegafri was to be used to treat a type of lung cancer called non-small cell lung cancer (NSCLC) in adults who have the T790M mutation (a particular change in the gene for a protein called epidermal growth factor receptor or EGFR) and who had already been treated with EGFR-targeted therapy.
Estonian: Xegafrit kavatseti kasutada teatud tüüpi kopsuvähi, mitteväikerakk-kopsuvähi (NSCLC) raviks täiskasvanutel, kellel on T790M-mutatsioon (teatud valku - epidermaalse kasvufaktori retseptorit (EGFR) - tootva geeni teatud muutus) ning kes olid juba saanud EGFR-ile suunatud ravi.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Xegafri did not outweigh its risks.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et Xegafri kasulikkus ei ole suurem kui sellega kaasnevad riskid.
English: Unlike most other tyrosine kinase inhibitors, rociletinib targets cancer cells with the T790M mutation in the EGFR gene.
Estonian: Erinevalt enamikust türosiinkinaasiinhibiitoritest on rosiletiniib aktiivne EGFRi geeni T790Mmutatsiooniga vähirakkude vastu.
English: Xegafri is being investigated in two studies in 457 NSCLC patients who have the T790M mutation and had already been treated with EGFR-targeted therapy.
Estonian: Xegafrit uuriti kahes uuringus, milles osales 457 T790M-mutatsiooniga patsienti, kes olid saanud EGFRile suunatud ravi.
English: How is Xegafri expected to work?
Estonian: Milline on Xegafri eeldatav toime?
English: Based on the review of the data, at the time of the withdrawal, the CHMP had had some concerns and was of the provisional opinion that Xegafri could not have been approved for the treatment of NSCLC patients who have the T790M mutation.
Estonian: Tuginedes esitatud andmete analüüsile, nägi inimravimite komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ning oli esialgsel seisukohal, et Xegafri kasutamist mitteväikerakk-kopsuvähiga ja T790M-mutatsiooniga patsientide raviks ei ole võimalik heaks kiita.
English: What was Xegafri expected to be used for?
Estonian: Milleks kavatseti Xegafrit kasutada?
English: This means that it blocks the activity of enzymes known as tyrosine kinases, particularly tyrosine kinases that are present in EGFRs.
Estonian: Xegafri toimeaine rosiletiniib on türosiinkinaasiinhibiitor ehk aine, mis blokeerib ensüümide türosiinkinaaside, eriti EGFR-ides leiduvate türosiinkinaaside aktiivsust.
English: 1 ml (100 mg/ml) 2 (2 x 1) pre-filled syringes (multipack)
Estonian: 2 (2 x 1) süstlit (mitmikpakend)
English: 1 ml (100 mg/ml) 2 (2 x 1) pre-filled pens (multipack)
Estonian: 2 (2 x 1) pensüstlit (mitmikpakend)
English: Invented name Strength Pharmaceutical Form
Estonian: Ravimvorm Manustamisviis Pakend Pakendi sisu Pakendi suurus
English: D-85540 Haar
Estonian: 85540 Haar
English: 1000 Ljubljana Slovenia
Estonian: SI-1000 Ljubljana Sloveenia
English: 00191 Roma
Estonian: I-00191 Roma
English: Farmacox - Companhia Farmacêutica Sociedade Unipessoal, Lda.
Estonian: Farmacox-Companhia Farmacêutica, Lda.
English: Via Benedetto Croce, 37 56125 Pisa
Estonian: Via Benedetto Croce, 37 I-56125 Pisa Itaalia
English: Riga, LV-1013
Estonian: LV-1013 Riga
English: Via G. Fabbroni 6 00191 Roma Italy
Estonian: Via G. Fabbroni, 6 I-00191 Roma Itaalia
English: Box 581
Estonian: Post Bus 581
English: [Very Common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1000 to <1/100) Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000), not known (cannot be estimated from the available data)]
Estonian: (Väga sage (>1/10), sage (>1/100, <1/10), aeg-ajalt (>1/1000, <1/100), harv (>1/10000, <1/1000), väga harv (<1/10000, sealhulgas üksikjuhud))
English: However no treatment-related external or skeletal foetal malformations were observed.
Estonian: Küülikutel täheldati raviga mitte seotud loote väliseid või skeleti väärarenguid.
English: Hertfordshire EN11 9BU
Estonian: Hertfordshire EN11 9BU Ühendkuningriik
English: NL-2003 PC Haarlem The Netherlands
Estonian: 2003 PC Haarlem Holland
English: ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS / MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
Estonian: LISA I RAVIMPREPARAATIDE NIMED, RAVIMVORMID, TUGEVUSED, MANUSTAMISVIIS JA MÜÜGILOA HOIDJAD LIIKMESRIIKIDES NING NORRAS JA ISLANDIL
English: For a full list of excipients, see section 6.1.
Estonian: Abiained vt lõik 6.1.
English: Av. da Siderurgia Nacional S. Mamede do Coronado Portugal
Estonian: Da Siderurgia Nacional 4745-457 S. Mamede do Coronado Portugal
English: Use of gastroprotective agents and low dose aspirin were permitted in the studies.
Estonian: Uuringus oli lubatud kasutada magu kaitsvaid aineid ja väikeses annuses Aspirin'i.
English: Etoricoxib
Estonian: Etoricoxibum
English: 00-867 Warsaw Poland
Estonian: Puławska 303 02-785 Warszawa Poola
English: Tablet coating: carnauba wax, lactose monohydrate, hypromellose, titanium dioxide (E171), triacetin.
Estonian: Tableti kate: karnaubavaha, laktoosmonohüdraat, hüpromelloos, titaandioksiid (E171), glütserooltriatsetaat.
English: The effect of the recommended chronic doses of etoricoxib (30, 60, and 90 mg) has not been studied.
Estonian: Etorikoksiibi kroonilise ravi soovitatud annuste (60 mg ja 90 mg) mõju ei ole uuritud.
English: The 30-, 60- and 120-mg tablets also contain indigo carmine lake (E132) and yellow ferric oxide (E172).
Estonian: 60 mg ja 120 mg tabletid sisaldavad ka indigokarmiini (E132) ja kollast raudoksiidi (E172).
English: ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET PRESENTED BY THE EMEA
Estonian: LISA II EUROOPA RAVIMIAMETI POOLT ESITATUD TEADUSLIKUD JÄRELDUSED JA RAVIMI OMADUSTE KOKKUVÕTTE MUUTMISE ALUSED